Furthermore, our data showed that after the second dose, T-cells produced less IFN-γ in cancer patients similar to what was reported in healthy individuals [43], which may indicate a downregulation in the immune response by regulatory T-cells (Treg) similar to healthy individuals. Here, IFNG is linked to cancer.